Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abivax S.A.
Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
Coronavirus Notebook: New Therapeutic Approaches, Fair Access To Dexamethasone, & Patent Help From The EPO
With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.